iRhythm Technologies
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: San Francisco, California, United States, North America
Region: California
Country: US
Continent: North America
About
iRhythm provides end-to-end cardiac monitoring solutions centered on Zio ECG monitors and a comprehensive service ecosystem. The offering combines patient-friendly wearables with data collection, AI-assisted analysis, and clinician-facing reporting to support accurate arrhythmia diagnosis. The company emphasizes high patient compliance, high diagnostic yield, and seamless data integration for healthcare professionals across the United States and global markets. iRhythm positions itself as transforming cardiac monitoring with a patient-centric, data-driven approach.
iRhythm Technologies provides ambulatory cardiac monitoring solutions, primarily through its Zio patch wearable device. The company offers a service ecosystem that includes data collection, AI-assisted analysis, and reporting to help clinicians diagnose arrhythmias. Its customers are healthcare providers and patients in the United States and global markets.
iRhythm Technologies, Inc.
2006
for_profit
active
Industries
Primary Industry: Manufacturing
Categories
Funding & Financials
Public Company
1100000000
200m-1b
ipo
NASDAQ:IRTC
nasdaq
Investors
Founders
Uday Kumar
Leadership
Douglas J. Devine — Chief Operating Officer
Mark Day — Executive Vice President, Research & Development
David Stoffel — Vice President, Operations - Mobile Cardiac Telemetry
Harveen Sethi — Director of Product Management
Alyce Green — Director Of User Experience
Andy Gilbert — Senior Machine Learning Scientist
Mudit Jain — Venture Capital Investor
Rohit Anand — Supplier Quality Specialist
Ralph Snyderman — board_member
Technology Stack
Products
Zio® ECG Monitors: Wearable adhesive cardiac monitors that continuously record heart rhythms for up to 14 days to detect arrhythmias.
ZioSuite®: A clinician portal and mobile app for interpreting cardiac monitoring reports and managing patient data.
MyZio® Patient App: A mobile application that supports patients during cardiac monitoring by enabling symptom logging and providing educational content.
Zio® Long-Term Continuous Monitoring (LTCM) Service: A cardiac monitoring service using Zio® devices to provide continuous, uninterrupted ECG data for arrhythmia diagnosis over extended periods.
MyZio SMS Text Messaging Service: A text messaging service providing patients with notifications and information related to their prescribed Zio® heart monitoring.
Funding rounds
POST_IPO_CONVERTIBLE · 575000000 · (2024-03-01T00:00:00)
POST_IPO_EQUITY · 220000000 · (2020-08-01T00:00:00)
DEBT · 65000000 · (2015-01-01T00:00:00)
SERIES_E · 17000000 · (2014-05-01T00:00:00)
SERIES_D · 16000000 · (2013-04-01T00:00:00)
EARLY_VC · 22150000 · (2012-01-01T00:00:00)
SERIES_C · 7000000 · (2011-10-01T00:00:00)
SERIES_B · 6500000 · (2009-05-01T00:00:00)
SERIES_A · 12000000 · (2007-02-01T00:00:00)
